BASF divests Omega-3 production plant
BASF has signed a definitive agreement to sell its manufacturing facility for natural fish oils, medium-concentrated omega-3s, and customized bottled fish oil in Brattvåg, Norway, to Marine Ingredients, a leading manufacturer of quality marine-based ingredients and customized products. Both parties agreed not to disclose financial details of the transaction, which is expected to be closed in Q1, 2015.
As part of the agreement, the 47 employees currently working in Brattvåg will transfer from BASF to Marine Ingredients. With the acquisition, Marine Ingredients will gain control of omega-3 production, which is central to its business, thus expanding its ability to serve customers with tailor-made omega-3 products.
BASF focuses its activities on the market segment for highly concentrated omega-3 fatty acids, following the acquisitions of Equateq (now BASF Pharma Callanish) in 2012 and of Pronova Biopharma in 2013. Highly concentrated omega-3 fatty acids for consumer health, clinical nutrition and pharmaceutical products are one of the key growth areas for BASF’s Nutrition & Health division.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV
Ablynx reports detailed positive Phase Ib results for its anti-thrombotic nanobody ALX-0081

Biologists examine sperm quality on the basis of their metabolism
Metabolism, Maths, Medicine: If Bacteria Were Calculable
Transgene: First Patient enrolled in Phase I Trial of TG4023 for the Treatment of Liver Tumours
Biovitrum completes acquisition of Cambridge Biotechnology Ltd
Two Patents for Use of Dyax' DX-88 in cardiothoracic surgery
European Regulatory Committee Recommends Orphan Drug Status for GPC Biotech's Anticancer Monoclonal Antibody
Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
